Abstract
Scleroatrophic lichen (lichen sclerosus) is a benign progressive disease characterized by marked skin inflammation, epithelial thinning, and itching. The etiology of scleroatrophic lichen is unknown. Autoimmune, hormonal, inflammatory, and genetic factors are indicated in the pathogenesis of the disease. Dominant clinical manifestations include marked itching, tissue thinning, dyspareunia, and dysuria. Chronic inflammation gradually leads to irreversible changes in tissue architectonics. Topical glucocorticosteroids for 4–6 weeks are the first-line treatment for scleroatrophic lichen. To improve tissue trophism, the combined use of topical agents with hyaluronic acid and lanolin is effective. Key words: scleroatrophic lichen, lichen, vulvodynia, topical glucocorticosteroids, dyspareunia, hyaluronic acid, lanolin, superlymph
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
